A federal regulation requiring drug manufacturers to ensure their copay assistance goes only to patients in order for the firms to be allowed to exclude the value of the assistance from Medicaid “best price” calculations was struck down by the US District Court for the District of Columbia in a 17 May decision.
The ruling grants a request from the Pharmaceutical Research and Manufacturers of America for a preliminary injunction barring implementation of...







